Aktis Oncology, Inc. (AKTS) Financial Statements
Industry: Pharmaceutical Preparations
Open the full interactive Aktis Oncology financials → Quarterly statements, key ratios, valuation history and price charts.
Aktis Oncology Key Stats
| Share Price | $16.64 |
|---|---|
| 52-Week Range | $15.19 – $32.23 |
| Shares Outstanding | 55.3 million (basic, 2026 Q2) |
Aktis Oncology Quarterly Results
| 2026 Q1 | 2026 Q2 | |
|---|---|---|
| Revenue | $3.2M | $3.4M |
| Net Income | -$18.3M | -$24.1M |
| Diluted EPS | -$0.38 | -$0.44 |
Figures from Aktis Oncology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Aktis Oncology financials page for every line item.
Aktis Oncology Company Profile
| Ticker | AKTS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0002035832 |